華納藥廠(688799.SH):已獲批的呼吸類產品有吸入用乙酰半胱氨酸溶液、吸入用硫酸沙丁胺醇溶液
格隆匯8月1日丨有投資者向華納藥廠(688799.SH)提問:請公司介紹一下呼吸類產品的佈局情況。
華納藥廠回覆:公司已獲批的呼吸類產品有吸入用乙酰半胱氨酸溶液、吸入用硫酸沙丁胺醇溶液。吸入用乙酰半胱氨酸溶液是公司近年來增長較快的製劑品種,2022年公司呼吸系統領域製劑產品實現營業收入23,994.28萬元,比上年增長23.89%,其中吸入用乙酰半胱氨酸溶液銷售量超4,800萬支,比上年增長85.71%。此外,公司2022年提交了吸入用異丙託溴銨溶液、鹽酸左沙丁胺醇霧化吸入溶液、吸入用複方異丙託溴銨溶液等多個呼吸類藥品註冊申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.